Clinical trials: Leucovorin
Metastatic Colorectal Cancer
FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer
The purpose is to study the efficacy (effectiveness) of a new drug, MK-0646, in metastatic colorectal cancer. MK-0646 is an investigational or experimental anti-cancer agent that has not yet been approved by the U.S.
- Trial name
- NCT01175291
- Testing
- MK-0646
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Gastric Cancer, Adenocarcinoma of the Esophagogastric Junction
Prospective Study With FLOT in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction
Patients with locally advanced or metastatic gastric carcinoma or carcinoma of the esophagogastric junction without prior palliative therapy will be treated with 8 cycles of the FLOT scheme (up to 12 cycles if the response is…
- Trial name
- FLOT3 (NCT00849615)
- Testing
- Docetaxel, 5-Fluorouracil, Oxaliplatin
- Where
- Germany
- Volunteers
- 252 people
- Sponsor
- Krankenhaus Nordwest
Metastatic Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8
Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
This phase I trial studies the side effects and best dose of CA-4948 when given together with fluorouracil, leucovorin, oxaliplatin (FOLFOX) plus bevacizumab in treating patients with colorectal cancer that has spread from where…
- Conditions
- Metastatic Colorectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Adenocarcinoma
- Trial name
- NCT06696768
- Testing
- Bevacizumab, Biopsy Procedure, Biospecimen Collection
- Where
- 13 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Digestive System Tumor
A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors
This is a prospective, open-label, exploratory, phase II basket clinical trial designed to evaluate the efficacy and safety of sintilimab in combination with pyrotinib with or without chemotherapy in patients with advanced…
- Trial name
- CCGLC-018 (NCT07053150)
- Testing
- Sintilimab, Pyrotinib, Optional Chemotherapy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma
The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Beyond Milan Criteria BCLC Stage A/B Hepatocellular Carcinoma Who Underwent Hepatectomy
To compare the impact on survival of neo-adjuvant TAI for patients with beyond Milan criteria BCLC stage A/B HCC who underwent hepatectomy.
- Trial name
- NCT03851913
- Testing
- TAI
- Where
- China
- Volunteers
- 344 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer
Combination Chemotherapy and Radiation Therapy in Treating Patients With Recurrent Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00268333
- Testing
- fluorouracil, leucovorin calcium, oxaliplatin
- Where
- 9 sites in France
- Volunteers
- 39 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Nasopharyngeal Carcinoma
Comparison the Effects of Different Neoadjuvant Chemotherapy Regimen on Acute Toxicity, Tumor Response, and Survival in Patients With Advanced Nasopharyngeal Carcinoma
The purpose of this study is to investigate the impact of different neoadjuvant chemotherapy schedules of cisplatin and 5-FU on acute toxicity, tumor response, and long-term survival in patients with advanced nasopharyngeal…
- Trial name
- NCT02500940
- Testing
- Cisplatin, Fluorouracil, Radiation therapy
- Where
- Taiwan
- Volunteers
- 54 people
- Sponsor
- Taichung Veterans General Hospital
Mixed Hepatocellular-cholangiocarcinoma
HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)
To evaluate HAIC combined with Camrelizumab plus rivoceranib for advanced mixed hepatocellular-cholangiocarcinoma (HCC-CCA).
- Trial name
- TASK-05 (NCT07105748)
- Testing
- Camrelizumab, Rivoceranib (Apatinib), HAIC
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Fudan University
Colorectal Cancer
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
PURPOSE: This randomized phase III trial is studying cetuximab and/or bevacizumab when given together with combination chemotherapy to compare how well they work in treating patients with metastatic colorectal cancer.
- Trial name
- NCT00265850
- Testing
- bevacizumab, cetuximab, FOLFOX or
- Where
- 683 sites in United States, Canada
- Volunteers
- 2,334 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Colorectal Cancer
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
The purpose of this study is to see if Cediranib in combination with FOLFOX is effective in treating metastatic colorectal cancer and to see how it compares with Avastin (Bevacizumab) in combination with FOLFOX.
- Trial name
- HORIZON III (NCT00384176)
- Testing
- Cediranib, Bevacizumab, 5-fluorouracil ( in FOLFOX)
- Where
- 280 sites in United States, Australia and 26 more
- Volunteers
- 1,814 people
- Sponsor
- AstraZeneca
Metastatic Pancreatic Cancer
A Multi-center, Single-arm, Prospective Non-interventional Study to Investigate the Safety Profiles and Effectiveness of Liposomal Irinotecan (ONIVYDE®) in Combination with 5-fluorouracil (5-FU) and Leucovorin (LV) in Chinese Patients with Metastatic Pancreatic Cancer As Approval Condition (SEOPAC)
The aim of this phase 4 study is to evaluate the safety profile of ONIVYDE in China mainland. Primary objective To characterize the safety of ONIVYDE when used under standard clinical practice in China mainland on the following…
- Trial name
- SEOPAC (NCT06688240)
- Volunteers
- 120 people
- Sponsor
- Servier (Tianjin) Pharmaceutical Co. LTD.
CRC
Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer
The purpose of this study is to compare whether a 3-month treatment is at least not inferior to a 6-month treatment (FOLFOX-4 6 vs. 12 cycles or XELOX 4 cycles vs.
- Trial name
- NCT01308086
- Testing
- 5-Fluorouracil, Leucovorin, Oxaliplatin
- Where
- Greece
- Volunteers
- 2,000 people
- Sponsor
- Hellenic Oncology Research Group
Gastric Cancer, Metastases
Phase III Trial of DP Followed by FOLFIRI or the Reverse Sequence in Unresectable Gastric Cancer
To assess the optimal sequence of the palliative chemotherapy regimen (DP --> FOLFIRI vs FOLFIRI --> DP) in metastatic gastric cancer patients.
- Trial name
- NCT00313872
- Testing
- DP, FOLFIRI
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Samsung Medical Center
Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor Anvumetostat administered in combination with other therapies in adult participants with metastatic…
- Trial name
- MTAPESTRY 103 (NCT06360354)
- Testing
- Anvumetostat, Gemcitabine, Nab-paclitaxel
- Where
- 77 sites in United States, Australia and 14 more
- Volunteers
- 120 people
- Sponsor
- Amgen
Resectable Pancreatic Cancer
Borderline Pancreas Study: FOLFIRINOX +SBRT
Primary Objective: To determine the rate of downstaging to resectability in patients with borderline resectable pancreatic cancer receiving FOLFIRINOX and SBRT as preoperative therapy. Secondary Objective(s): 1.
- Trial name
- GCC 1324 (NCT01992705)
- Testing
- Chemotherapy(FOLFIRINOX) + SBRT prior to surgery if applicable, -Oxaliplatin 85 mg/m2 IV on Day 1, -Irinotecan 180 mg/m2 IV on Day 1
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Maryland, Baltimore
Metastatic Colorectal Cancer
Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer
This is a two arm, 2-center, Phase II, study of 5-FU, irinotecan, bevacizumab (FOLFIRI-beva) and hydroxychloroquine (HCQ) in patients with previously untreated metastatic colorectal cancer (mCRC).
- Trial name
- NCT05843188
- Testing
- Hydroxychloroquine, Irinotecan, Leucovorin
- Where
- 2 sites in Canada
- Volunteers
- 155 people
- Sponsor
- University Health Network, Toronto
Metastatic Pancreatic Cancer
Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer
The purpose of this study is to provide a go/no-go decision for a randomized expansion study by assessing the disease control rate (DCR) at 6 weeks for the combination of olaptesed pegol on top of pembrolizumab and (Arm 1)…
- Trial name
- OPTIMUS (NCT04901741)
- Testing
- Olaptesed pegol, Pembrolizumab
- Volunteers
- 60 people
- Sponsor
- TME Pharma AG
Colorectal Neoplasms Malignant
The Effects of RFA in Combination With Second-line Chemotherapy and Bevacizumab on Unresectable CRLM
Basing on the strong evidence from former researches, patients with CRLM can benefit from the treatment of bevacizumab combined with sencond-line chemotherapy.
- Trial name
- NCT03686254
- Testing
- RFA, bevacizumab and second-line chemotherapy, Bevacizumab and second-line chemotherapy
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Metastatic Colorectal Cancer
Circulating Regulatory Lymphocytes and Outcome of Metastatic Colorectal Cancer Patients
Aim of the present study is to investigate whether baseline or early post-treatment (one month after treatment commencement) frequency of peripheral T regulatory lymphocytes (Tregs OR CD4+/CD25high/FOXP3+ T cells), known to…
- Trial name
- NCT01533740
- Testing
- fluorouracil/irinotecan/levo-folinic acid/bevacizumab
- Where
- Italy
- Volunteers
- 31 people
- Sponsor
- University of Rome Tor Vergata
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma
The ongoing study is a Phase II, open-label study to evaluate the efficacy of MBP-426 at a dose of 170 mg/m2 in combination therapy in patients with second line metastatic gastric, gastro-esophageal junction or esophageal…
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT00964080
- Testing
- MBP-426/Leucovorin/5-FU
- Where
- 5 sites in United States, Georgia
- Volunteers
- 62 people
- Sponsor
- Mebiopharm Co., Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.